Aceragen, Inc. Stock Nyse
Equities
ACGN
US00445F1093
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | 4.86M | Capitalization | 3.12M |
---|---|---|---|---|---|
Net income 2021 | 98M | Net income 2022 | -23M | EV / Sales 2021 * | - |
Net cash position 2021 * | - | Net cash position 2022 * | - | EV / Sales 2022 * | - |
P/E ratio 2021 * |
-
| P/E ratio 2022 * |
-
| Employees | 26 |
Yield 2021 * |
-
| Yield 2022 * |
-
| Free-Float | 38.12% |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |